ANTITHROMBOTIC COMPOUNDS

Abstract: This invention is concerned with certain trlphenyl­ imidazoles compounds of formula (I) in which R and R′ are identical or different and may be hydrogen; a lower alkyl having 1 to 4 carbons; phenyl; phenyl substituted with one or more lower alkyl groups having from 1 to 4 carbons, lower alkoxy groups having from 1 to 4 carbons or halogen atoms, e.g. Br or Cl; phenylalkyl (optionally substituted on the phenyl ring with one or more lower alkyl groups having from 1 to 4 carbons, lower alkoxy groups having 1 to 4 carbons or halogen atoms, e.g. Br or Cl); or taken together from a cyclic substituent of 5 or 6 members containing in addi­ tion to the nitrogen atom an optional second hetero atom selected from the groups consisting of oxygen nitrogen and sulfur. This invention is also taken to in­ clude the acd addition salts and solvates of the com­ pounds of formula (I). These compounds are useful as antithrombotic, anti­ inflammatory, antipyretic and analgesic agents.

Description: ANTITEROMBOTIC COMPOUNDS This invention relates to compounds useful in medicine, to the preparation of such compounds, to pharmaceutical formulations containing such compounds and the preparation of such formulations, and to the use of the compounds in medicine. Platelets, the smallest formed elements of the blood, play an important role in hemostasis by stopping the outward flow of blood through ruptures in the blood vessel wall. They aggregate or fuse together at the site of injury to form a temporary plug or clot which seals the blood vessel. The clumping together of the platelets initiates a chain of biochemical reactions which leads to the reinforcing of the clot with the fibrous protein, fibrin. Aggregation of platelets appears to be triggered by their contact with certain surfaces, such as the basement membranes of the blood vessels or collagen fibrils. Once aggregation has begun, the platelets stick to each other. It is clear that the ability of platelets to aggregate and initiate thrombus formation is important to protect the organism from excessive loss of blood as a result of injury. However, in some individuals, platelets will begin to adhere to the inner walls of the blood vessels as a result of a disease process. As more platelets accumulate, a blood clot may form which restricts the amount of blood flowing through the vessel. This can result in the interruption of blood flow to a vital organ such as the heart, for example, thereby causing a heart attack. A thrombus formed in this way may also become dislodged and travel as an embolus through the circulatory system. In such a case, there is a risk that the embolus could become lodged in vessels supplying organs such as the brain or ssang and could restrict the flow of blood so much that the function of these organs would be severely impaired. This could be fatal or render the individual Disabled. Further general discussions of blood platelets are presented by S. B. Kahn, American Family Physician, Vol. 21 No. 5, 166, (1980) and M. B. Zucker, Scientific American Vol 242, p 86, June (1980) and Vol 204, p 58, February (i961). It is clear from the foregoing discussion that it is desirable under some situations to reduce or prevent the aggregation of blood platelets in vivo in under to avoid the pathological disturbances to the cardiovascular system noted above. It is an object of the present invention to provide a class of compounds which have been found to possess an advantageous inhibitory effect upon the aggregation of blood platelets. These compounds have, in addition, been found to possess useful anti-inflammatory, anti-pyretic and analgesic activities, as discussed in more detail below. In particular, the present invention relates to compounds of Formula (I), EMI3.1 in which R and R' are identical or different and may be hydrogen; a lower alkyl having 1 to 4 carbons, eg., methyl or ethyl; phenyl; phenyl substituted with one or more (eg., 1 or 2) lower alkyl groups having from 1 to 4 carbons, eg., methyl or ethyl, lower alkoxy groups having from 1 to 4 carbons, eg., methoxy or ethoxy, or halogen atoms, e.g. Br or C1; phenyl-C 4-alkyl (optionally substituted on the phenyl ring with one or more (eg., 1 or 2) lower alkyl groups having from 1 to 4 carbons, eg., methyl or ethyl, lower alkoxy groups having 1 to 4 carbons, eg., methoxy or ethoxy or halogen atoms, e.g. Br or C1); or taken together with adjacent nitrogen atom form a cyclic substituent of 5 or 6 members containing in addition to the nitrogen atom an optional second hetero atom selected from the group consisting of oxygen, nitrogen and sulfur. Any reference hereinafter to the compounds of Formula (I) may be taken to include reference to the acid addition salts and solvates including hydrates thereof. The therapeutic activities of these compounds reside in the base so that useful acid addition salts may be prepared from various acids which are pharmaceutically acceptable. Representative acid salts include but by no means are limited to hydrochloride (mono and di), hydrogensulfate (mono and di), isethionate (mono and di), sulfate, maleate, mesylate (mono and di), diphosphate, and ditartrate. The preferred embodiment of this invention relates to compounds of Formula (I) in which R and R' are identical or different and may be hydrogen, a lower alkyl having 1 or 2 carbons, phenylmethyl (benzyl), or phenylethyl (optionally substituted on the phenyl ring with one or two methoxy, methyl or chloro groups) or taken together with the adjacent nitrogen atom form a cyclic substituent of 5 or 6 members containing in addition to the nitrogen atom an optional second hetero atom which is oxygen or nitrogen. Of the preferred embodiment, the following compounds have been found to be tarticularly useful: 2-[2-(2-Aminoethoxy)phenyl]-4,5-diphenylimidazole (Ia) 2-{2-[2-(Methylamino)ethoxy]phenyl}-4,5-diphenylimidazole (Ib) -(2- [2- (liethylamino)ethoxy)phenyl)-4 ,5-diphenylimidazole (Ic) 2- (2- [2- (N-Methylbenzylamino)ethoxy)phenyl-4,5-diphenylimidazole (Id) 2- {2- [2- (4-Methoxy-N-methylbenzylamino)ethoxy]phenyl)-4 ,5- (Ie) diphenylimidazole 2- (2- [2- (3, 4-Dimethoxy-N-methylbenzylamino)ethoxyphenyl)- (If) 4 ,5-diphenylimidazole 2-(2-[2-(N,4-dimethylbenzylamino)ethoxy]phenyl)-4,5- (Ig) diphenylimidazole 2-{2-[2-(4-Chloro-N-methylbenzylamino)ethoxylphenyl}- (Ih) 4,5-diphenylimi-dazole 4,s-Diphenyl-2-(2-[2-(N-propylbenzylamino)ethoxy]phenyl)imidazole (Ii) 2-(2- [2-(tibenzylamino)ethoxy]phenyl)-4,5-diphenylimidazole (Ij) 2-(2-[2-(N-Methylphenethylamino)ethoxy]phenyl)-4,5- (Ik) diphenylimidazole 4,S-Diphenyl-2-[2-(2-piperidinoethoxy)phenyl) imidazole (I) 2-[2-(2-Morpholinoethoxy)phenyl]-4,5-diphenylimldazole (Im) 4,5-Diphenyl-2-{2-[2-(1-pyrrolidinyl)ethoxy]phenyllimidazole (In) The most preferred embodiment of this invention is the compound of Formula (II) (including its pharmaceutically acceptable acid addition salts such as hydrochloride, sulfate, phosphate, isethionate, and solvates including the hydrate) also known as 2-{2- [2-(dimethylamino)ethoxyiphenyl).4,5-diphenyl- imidazole hereinafter referred to as the "Compound II." EMI5.1 The compounds of Formula (I) and their physiologically acceptable acid addition salts and solvates are useful for the treatment or prophylaxis of thrombo-embolic conditions in a mammal, such conditions including those whose etiology is associated with platelet aggregation. The compounds of Formula I have been found, when it is desired to inhibit platelet aggregation, to prevent the formation of thrombi in mammals, including man. For example these compounds would be useful in prevention of myocardial infarctions, transient ischemic attacks (TIA's), strokes, post-operative thrombosis (including that incurred after artificial heart valve or hip replacement), central retinal vein occlusions and the atherosclerotic process that leads to a variety of conditions including peripheral vascular diseases and renal vascular hypertension. Other treatable conditions include diabetic retinopathy, thrombotic thrombocytopenia purpura and migraine. Compounds of Formula (I) would be useful in maintaining A-V shunt patency in uremic patients maintained on hemodialysis. They may also be used as additives to blood, blood products, blood substi tutes, and other fluids which are used in artificial extra-corporeal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or prepared for transplant, or attached to a new body. During these circulations and perfusion, aggregated platelets tend to block the blood vessels and portions of the circulation apparatus. This blocking may be avoided by the presence of the compounds of Formula (I). The compounds of Formula (I), especially the compound II, are also useful as substitutes for nonsteroidal drugs in treatment of fever, acute inflammation, and rheumatoid arthritis. One important advantage of the above compounds is that they have been found to be relatively devoid of gastric effects shown in animal models. Compound II is useful as a substitute for aspirin, indomethacin, and other non-steroidal anti-inflammatory agents in the treatment of acute inflammation and fever. Another important advantage of the compounds of Formula (I) is the high s31ubility of their di-acid salts. This is a very useful property since it allows these compounds to be used in an injectable form. The compounds of Formula (I) may be used in the relief, treatment or prophylaxis of pain, inflammation and/or fever in a mammal, including man, such as: that resulting from headache, toothache, pain following general dental procedures, oral and general surgery, dysmenorrhea, myalgia, pain of unresectable cancer, joint and peripheral nerve disorders, rheumatoid arthritis, rheumatoid spondylitis, osteo-arthritis, gouty arthritis, pyresis and other conditions associated with pain, inflammation and/or fever. The amount of active compound required for use in the above conditions will, of course, vary both with the route of administration, the condition under treatment and the mammal undergoing treatment, and is ultimately at the discre tion of the physician. However, a suitable antithrombotic, analgesic, antiinflammatory and/or anti-pyretic oral dose of the active compound for a mammal is in the range of from 1 to 100 mg per kilogram body weight per day; a typical dose of, e.g., Compound II for a human recipient being 30 mg/kg body weight per day. The desired dose is preferably presented as from one to three sub-doses administered at appropriate intervals throughout the day. Thus, where two subdoses of Compound II are employed each will preferably lie in the range of from 0.5 to 30 mg/kg body weight; a typical subdose for a human recipient being about 10 mg/kg body weight. While it is possible for the active compound to be administered (at an appropriate dose) alone, it is preferable to present it as a pharmaceutical formulation. Formulations of the present invention, both for veterinary and for human medical use, comprise the active compound together with one or more pharmaceutically acceptable excipients therefor and optionally any other desired therapeutic ingredient. The excipient(s) or carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The other therapeutic ingredient(s) may include: caffeine; other analgesics, anti-inflammatories or anti-pyretics such as aspirin or codeine; antitussives; expectorants; bronchodilators; or anti-histamines. The formulations of the present invention include those suitable for oral, rectal or parenteral (including subcutaneous, intraperitoneal, intramuscular and intravenous) administration. The formulations may be adapted to provide for rapid, prolonged or delayed release of the active compound to effect different rates of onset and/or duration of therapeutic effect. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with one or more excipient(s). In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid, a semisolid, a bulk solid or a polymeric material, or a combination thereof, and then forming the product into desired formulation. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules (soft or hard gelatin), cachets, tablets (coated or uncoated), lozenges or boluses, each containing a predetermined amount of the active compound; or as solutions or suspensions of the active compound for effective treatment in a aqueous liquid, or a combination thereof such as: a syrup, an elixir, a draught, a solution, a suspension, a linctus or a drench; or as an oil-in-water emulsion, a water-in-oil emulsion or a multiple emulsion; a paste or a gel. Compounds of Formula (I) and their salts may be prepared by any method known in the art for the preparation of compounds of analogous structure. For the present-invention, the following processes are provided wherein "R" and "R"' have the same meaning as for compounds of Formula (I) herein before. 1) The reaction of a a,ss-diphenylethylene derivative with an appropriate 2(2-aminoethyloxy)phenyl derivative, eq. an aldehyde amidine, nitrile etc., to form the imidazole ring produces compounds of Formula (I). The ethylene derivative may be a,ss-diketone, an a-ketone with a leaving group in the ss position or an a-amino-ketone. With some reactions of this type, an ammonium derivative may be required as a source of nitrogen. Preferable embodiments of this method are: a) A compound of Formula (III) may be reacted with benzil and ammonium acetate. EMI9.1 This condensation may be effected in such a solvent as acetic acid at reflux temperature. The compounds of Formula (III) may be prepared by reacting a compound of formula HNRR' with the compound of Formula (IV). EMI9.2 where L is a suitable leaving group as defined by J. March, Advanced Organic Chemistry 3rd ed page 187 (1977), McGraw Hill, NY, eg. L = Halogen (such as bromine or chlorine) or other leaving group such as toluenesulfonate In turn, the compound of Formula (IV) wherein L is halogen may be prepared by the reaction of salicylaldehyde and 1,2-dihaloethane in an alkanol such as methanol at reflux temperature in the presence of a base such as sodium hydroxide. b) A compound of Formula (V) wherein "G" is a suitable leaving group such as halide, hydroxy, toluenesulfonate, etc., may be reacted with a compound of Formula (VI) in a suitable solvent with or without a catalyst, e.g., acid or base, present. EMI10.1 Compounds of Formula (VI) can be prepared from compounds of formula (VIa) by such a method as that described first by Pinner and Klein, Ber, 10, 1889 (1877), and more recently by Roger and Neilson, Chem. Rev., 61 179 (1961). EMI10.2 In turn compounds of Formula (VIa) may be prepared from 2-hydroxy benzonitrile by a similar procedure described herein above for the preparation of Formula (III). c) A compound of Formula (VII) may be reacted with a compound of Formula (VIII) in a suitable solvent. EMI10.3 EMI11.1 A compound of Formula (VIII) may be prepared from compounds of Formula VIa described before herein by such a method as that described by Pinner, Die Imidoether Und ihre Perivate, (Berlin, 1892), reprinted Ann Arbor, Mich., 1961, page 23. For a review of imino esters, see Neilson, in Patai, "The Chemistry of Amidines and Imidates," pp. 385-489, John Wiley & Sons, New York, 1975. d) A compound of Formula (VII) described in method C herein above may be reacted with a compound of Formula (IX). EMI11.2 The compounds of Formula (IX) can be prepared from 2-hydroxy benzamide by an analogous route to that for the compounds of Formula (III) described herein above. 2) Another method comprises a reaction of the compound of Formula (X) with a compound of Formula (XI) in the presence of a base in a suitable solvent. EMI12.1 wherein L is a leaving group such as that in Formula (IV) The Compound (X) can be prepared by condensation of benzil, ammonium acetate and salicylaldehyde in an analogous way to that described in method la. 3) A compound of Formula (XII) may be reacted with an appropriate amine, HNRR, in a suitable solvent preferably with a non-nucleophilic base present such as K2CO3. EMI12.2 The compound of Formula (XII) can be made from reacting the compound of Formula (X) with a compound of Formula (XIII), wherein L and L' are suitable leaving groups (such as those described in relation to L in Formula (IV) above, in a suitable solvent in the presence of a base. 4) The reaction of a compound of Formula I (wherein at least one of R and R' is hydrogen) with an appropriate alkylating, arylating or aralkylating agent, to provide a corresponding compound of Formula (I) (wherein at least one of R and R' is a lower alkyl, phenyl or phenyl-Cl 4-alkyl group as defined above). 5) A further method comprises the condensation of the compound of Formula (XIV) with a primary or secondary amine, HNRR' in the presence of a reducing agent such as hydrogen or sodium borohydride. EMI13.1 The compound of Formula (XIV) can be prepared by known methods of mild oxidation of compound formula (XV). EMI13.2 The Following Examples Illustrate the Present Invention Example 1 Preparation of 2-(2-[2-Dimethylamino)ethoxylphenyl)- 4,5-diphenylimidazole (Compound II) a. 2- (2-Bromoethoxy)benzaldehyde Salicylaldehyde (620 g, 5.08 mole), 1,2-dibromoethane (3814 g 20.3 mole) and methanol (5.0 liters) were heated to reflux, then with stirring, 6N sodium hydroxide (1.0 liter) was added in 100 mL portions with 30 minute intervals between additions. After 18 hours of stirring at reflux, the methanol was removed under reduced pressure (aspirator). Water (1.5 liters) was added to the resulting slurry and the mixture was extracted with dimethyl ether (2.5 liters). The organic phase was separated and filtered through ELITES brand filter aid to remove the solid material. The filtrate was then washed with 6N sodium hydroxide (3 x 250 mL) followed by water (3 x 500 mL). The ether layer was separated, dried over anhydrous K2C03, filtered and stripped of solvent on the steam bath. The resulting residue was crystallized from a 1:1 diethyl ether-pentane mixture, air dried and 2-(2-bromoethoxy)benzaldehyde, 565 g (48.5% theoretical yield), was obtained. An analytical sample was obtained by-column chromatography on silica gel using toluene as eluent, m.p. 58-60.50C. Elemental Analysis: Calcd. for C9K902Br MW 229.08 C 47.19; H 3.96 Found: C 47.21; H 3.92 b. 2-(2-Dimethylaminoethoxy)benzaldehyde Dimethylamine (25% aqueous solution, 1.2 liters), 2-(2-bromoethoxy)benzaldehyde (229 g, 1.0 mole) and methanol (4.0 liters) were stirred at ambient temperature for 60 hours. The reaction mixture was stripped of solvent at aspirator pressure on a steam bath to yield a light yellow residue. This residue was dissolved in 4N NaOH (500 mL) and extracted with three, 800 mL portions of ether. The ether extracts were combined, extracted with, 4N hydrochloric acid (4 x 125 mL) followed by washing with water (125 mL). The hydrochloric acid and water washes were combined and made alkaline with of 8N NaOH (250 mL), then extracted with diethyl ether (3 x 800 mL). The ether extracts were combined and washed with water (3 x 250 mL). The organic phase was dried with K2C03, filtered and stripped of solvent to yield the crude product. The crude material was distilled at high vacuum with 151 g (78.2% of theoretical yield) of 2-(2-dimethylaminoethoxy)benzaldehyde being collected at 101 C and 0.30 mm Hg. Elemental Analysis: Calcd. for CllK15N02 MW 193.25 C 68.37; H 7.82; N 7.25 Found: C 68.13; H 7.92; N 7.14 c. 2-(2-[2- (Dimethylamino)ethoxyjphenyl}4,5-diphenylimidazole Benzil (223 g, 1.06 mole), ammonium acetate (340 g, 4.41 mole), 2-(2dimethylaminoethoxy)benzaldehyde (228 g, 1.18 mole) and glacial acetic acid (700 mL) were refluxed for two hours then poured into ice and water (about 7 liters). Concentrated ammonium hydroxide (about 3 liters) was added in small amounts to make the mixture basic. The solid material was collected and recrystallized from methanol to yield 2-(2- [2- (dimethylamino)ethoxy)phenyl)4,5-diphenyl- imidazole, 297 g (73% of theoretical yield), m.p. 146.5-148.50C. Elemental Analysis: Calcd. for C2sH25N3O MW 383.47 C, 78.30; H, 6.57; N, 10.96. Found: C, 78.22; H 6.59; N, 10.94 Example 2 Preparation of 2-{2-[2-(N-methylben2ylamino)ethoxy]phenyl}- 4,5-diphenylimidazole (Id) a. 2- (2-N-Methylbenzylaminoethoxy)benzaldehyde Methylbenzylamine (26.6 g, 0.22 mole), 2-(2-bromoethoxy)benzaldehyde (23.0 g, 0.1 mole) and methanol (50 mL) were heated on a steam bath with stirring for 4 hr. The solvent was stripped at aspirator pressure on a steam bath to leave a redbrown liquid which was stirred with diethyl ether (500 mL) and then the methylbenzylamine hydrobromide was removed by filtration. The ether solution was extracted with 24% NaOH solution (2 x 25 mL) then extracted with 3N HC1 (4 x 25 mL). The acidic solution was made basic with 24% NaOH solution and then extracted with ether (4 x 100 mL). All ether extracts were combined and dried over K2C03, filtered and the solvent removed to give 26.3 g of red liquid. Water (50 mL) and acetic anhydride (50 mL) were added to the red liquid and stirred for an hour to convert the unreacted methylbenzylamine amine into the amide. Ether (-300 mL) was added and the resulting mixture was extracted with 3N HC1 (4 x 25 mL). The acid solution was made basic with NaOH (24% solution) and this alkaline solution was extracted with ether (4 x 152 mL). All the ether extracts were combined and dried over anhydrous K2C03. After filtering, removal of solvent yielded 25.8 g (96% of theoretical yield) of 2-(2-N-methylbenzylamino- ethoxy)benzaldehyde as a red-brown liquid. Elemental Analysis: Calcd. for CllH19N02 MW 269.3 C 75.81; H 7.11; N 5.20 Found: C 75.57; H 7.16; N 5.32 b. 2-{2-[2-(N-Methylbenzylamino)ethoxyaphenyl} 4,5-diphenylimidazole Benzil (16 g, 0.076 mole), ammonium acetate (23.1 g, 0.3 mole), 2-(2-methylbenzylaminoethoxy)benzaldehyde (20.5 g, 0.076 mole) and glacial acetic acid (120 mL) were refluxed for four hours then poured into of ice and water (about 500 mL). Concentrated ammonium hydroxide (28%) (about 225 mL) was added to make the mixture basic and the solid precipitate was collected and recrystallized from ethylacetate to yield 2-(2- [2-(methylbenzylamino)ethoxy]phenyl-4,5-diphenyl imidazole 16.6 g (47% of theoretical yield), mp. 206-2070C. Elemental Analysis: Calcd. for C31H29N30 MW 459.57 C 81.01; H 6.36; N 9.15 Found; C 81.12; H 6.35; N 9.15 Example 3 Preparation of 4,5-Diphenyl-2-[2-(2-piperidinoethoxy) phenyl]imidazole (IQ) a. 2-(2-Piperidinoethoxy)benzaldehyde The preparation was analogous to that described in example 2 except 1 molar equivalent of bromoethoxybenzaldehyde and 2.3 to 3 equivalents of piperidine were heated at reflux in methanol for three hours. The methanol was evaporated and the residue was worked-up as in example Ib. The 2-(2-piperidinoethoxy) benzaldehyde produced this way was used in its crude state in the below preparation, 3b. b. 4,5-Diphenyl-2-[2-t2-Piperidinoethoxy)Phenyl]imidazole Benzil, ammonium acetate and 2-(2-piperidinoethoxy)benzaldehyde were reacted in the same molar proportions and under the same conditions as in the analogous preparation disclosed in example lc. The yield of 2(2-[2-(piperidino)ethoxy]- phenyl)-4,5-diphenylimidazole after recrystallization from methanol was 75% with a mp of 184-1850C. Elemental Analysis: Calcd for C28H29N30 MW 423.53 C, 79.40; H, 6.90; N, 9.92 Found: C, 79.34; H, 6.89; N, 9.93 Example 4 Preparation of 2-C2-(2-MorpholinoethoIv)phenyll-4,5- diphenylimidazole (Im) a. 2-(2-horpholinoethoxy)benzaldehyde The preparation of 2-(2-morpholinoethoxy)benzaldehyde was the same as described in example 3a, except an appropriate amount of morpholine was used in place of piperidine. b. 2-12-(2-Morpholinoethoxy)phenyl)-4,5-diphenylimidazole The same procedure was used as described in example 3b, except 2-(2-morpholinoethoxy)benzaldehyde was used in place of 2-(2-piperidinoethoxy)benzaldehyde. The yield of 2t2-[2-(morpholino)ethoxy]phenyl}4,5-diphenylimidazole was 60%, and the mp was 173-1740C. Elemental Analysis: Calcd. for C27H2,N302 MW 425.54 C, 76.21; H, 6.40; N, 9.87 Found: C, 76.72; H, 6.40; N, 9.77 Example 4a Preparation of 2-(2-(2-Anilinoethoxy)phesyl]-4,5-Diphenylimidazole The preparation is analogous to that described in Example 2 except 1 molar equivalent of bromoethoxybenzaldehyde 2.5 to 3 molar equivalents of aniline are heated at reflux in methanol for three hours. The methanol is evaporated and the residue is reacted as in example lb. To produce 2-[2-(2-Anilinoethoxy)phenyl]- 4,5-diphenylimidazole. Example 5 Preparation of Acid Addition Salts of Compound II a. Preparation of 2-(2-[2-(Dimethylamino)ethoxy]phenyl)-4,5- diphenylimidazole sulfate, i.e. Compound II sulfate 12 g of Compound II was dissolved in 180 mL of methanol and 2.0 mL of sulfuric acid was slowly added. The product crystallized upon cooling and was collected, washed with ether and dried to give 10.3 g (64.7%) of Compound II sulfate; m.p. 145.5-1480C. Elemental Analysis: Calcd. for C25H25N3OH2SO4 1'wH20 C, 59.04; H, 5.95; N, 8.26 Found: C, 58.99; H, 5.99; N, 8.23 b. Preparation of Compound II maleate 2 g of Compound II was dissolved in 14 mL of toluene and 0.67 g of maleic acid dissolved in 5 mL acetone was added. The mixture was stirred vigorously. The product crystallized and was collected, washed with ether and dried to give 2.6 g (100%) of Compound II maleate; mp 131-133.50C. lemental Analysis: C25H25N30C4H4O4 C, 69.72; H, 5.85; N, 8.41 Found: C, 69.55; II, 5.92; N, 8.37 c. Preparation of Compound II dihydrochloride 250 g of Compound II was dissolved in 4 L of methanol at 55 . The solution was treated with 54 g of hydrogen chloride and 25 g Darco G-60 and stirred at reflux. The carbon was removed by filtration and the filtrate was concentrated to a 1 L volume, 2.5 L of ethyl acetate was added and the mixture was cooled. The product was collected, washed with ethyl acetate and dried to give 287 g (96.5) of Compound II dihydrochloride, mp 277-2800C. Elemental Analysis: Calcd. for C25H25N302HC1 C, 65.79; H, 5.96; N, 9.21; C1, 15.53 Found: C, 65.70; H, 5.97; N, 9.19; C1, 15.48 d. Preparation of Compound II hydrochloride (as monohydrate) a. 15.4 g of Compound II was dissolved in a mixture of 75 mL methanol, 60 mL water and 9 mL hydrochloric acid. The solution was treated with 2N NaOH, adjusting to pH 5.14, causing precipitation of the product. The product was collected, washed with water, slurried in acetone, recollected and dried to give 11.6 g (66%) of Compound II hydrochloride. Elemental Analysis: Calcd. for C25H25H30 HC1 H20 C, 68.56; H, 6.44; N, 9.59; C1, 8.09 Found: C, 68.38; H, 6.49; N, 9.55; C1, 8.05 e. Preparation of Compound II hydrochloride (as dihydrate) Compound II (1811.8 g, 4.73 mole), methanol (2,463 mL) and 1N hydrochloric acid (4,724.6 mL, 4.72 mole) were combined and heated to 600C. The mixture was cooled to -50C and the solids filtered. The white solids were vacuum dried at 500C giving 1,791 g on an anhydrous basis (90% of theoretical yield). Elemental Analysis: Calcd. for C25H25N30 HC1 2.03 H20 MW 456.52 C, 65.77; H, 6.64; N, 9.20; C1, 7.77 Found: C, 65.77; H, 6.62; N, 9.20; C1, 7.79 f. Preparation of Compound II diisethionate and isethionate 16 g of Compound II was dissolved in a solution of 7.56 g isethionic acid in methanol-water. The solution was concentrated to an oil which was redissolved in ethanol. The solution was diluted with acetone to crystallize Compound II diisethionate which was collected, washed and dried giving 10.0 g (47.1%); mp 113-1150C. The filtrate and wash were concentrated to a powder which was triturated with ethanol-acetone, collected and dried to give 5.6 g (26.4%) of Compound II isethionate; mp 87-890C. Elemental Analyses: Calcd. for C25H25N30-2C2H604S-2tH20 C, 51.16; H, 6.22; N, 6.17; S, 9.42 Found: C, 51.19; H, 6.24; N, 6.10; S, 9.43 Calcd. for C25H25N30C2H6O4S'2H20 C, 59.43; H, 6.47; N, 7.70; S, 5.88 Found: C, 59.45; H, 6.50; N, 7.66; S, 5.87 g. Acid addition salts of other compounds of Formula (I) may be prepared in a manner analogous to that described above. Example 6 Preparation of Other Compounds of Formula (I) a. The compounds listed in Table I were prepared in an analogous way to that described in Example 1. TABLE I Compound Melting Compound Number Point (OC) 2-[2-(2-Aminoethoxy)phenyl]-4,5-diphenyl- Ia 139-140 imidazole 2-(2-[2-(Methylamino)ethoxylphenyl)-4,5- Ib 135-136 diphenylimidaozle 2-{2-[2-(Diethylamino)ethoxy]phenyl}-4,5- Ic 79-80 diphenylimidazole b. The compounds listed in Table II were prepared in an analogous way to that described in Example 2 TABLE II Compound Melting Comound Number Point ( C) 2-(2-[2-(4-Methoxy-N-methylbenzylamino)- Ie 210-212 ethoxy [phenyl)-4,5-diphenylimidazole 2-{2-[2-(3,4-Dimethoxy-N-methylbenzylamino)- If 247-249 ethoxylphenyl)-4,5-diphenylimidazole 2-(2-[2-(N,4-Dimethylbenzylamino)ethoxy]- Ig 185-186 phenyl}-4,5-diphenylimidazole 2-{2-[2-(4-Chloro-N-methylbenzylamino)ethoxy]- Ih 223-225 phenyl) -4 ,5-diphenylimidazole 4,5-Diphenyl-2-(2-[2-(N-propylbenzylamino)- Ii 173-175 ethoxy]phenyl) imidazole <RTI ID=23.11> 2-(2-[2-(Dibenzylamino)ethoxy]phenyl)-4,5- Ij 123-125 diphenylimidazole 2-(2-[2-(N-Methylphenylamino)ethoxy]phenyl)- Ik 111-112 4,5-diphenylimidzole 1Dihydrochloride salt prepared from the base as described in Example 5 above. c. 4,5-Diphenyl-2-(2-[2-(1-pyrrolidinyl)ethoxy]phenyl)imidzole (In), mp 1541550C, was prepared in an analogous way to that described in Examples 3 and 4. Example 7 Inhibition of Platelet Aggregation a. In vitro studies: Concentrations of 2 pM or less partially inhibit, while 4pM completely inhibits arachidonate and collagen-induced aggregation of platelets from human, guinea pig, rat, and dog. In these tests, described by Born1, Compound II is at least 25-fold more potent than aspirin and equipotent to indomethacin. b. Ex vivo studies: The aggregation of platelets taken from animals dosed by the oral route with Compound II is inhibited when tested with arachidonate and collagen by the method of Born ((1962) Nature 194, 927, 929). The dose required to inhibit aggregation rate by 50% (ED50) at 1 hour was 5 mg/kg and 10 mg/kg in the guinea pig and rat, respectively. By comparison, the ED50 for aspirin in the guinea pig was 30 mg/kg, while the ED50 for aspirin in the rat was 10 mg/kg. The ED50 for indomethacin was 10 mg/kg and 5 mg/kg in the guinea pig and rat, respectively. In the dog, 10 mg/kg p.o. was an ED50 for as long as 6 hr. The second (release) phase of ADP-induced aggregation of dog platelets was also inhibited by 50% at 6 hours after 10 mg/kg p.o. Like indomethacin but unlike aspirin, the inhibition of aggregation by Compound II in the rat and guinea pig is reversible such that platelets taken 24 hours after dosing respond normally to aggregation stimuli. Example 8 Anti-thrombotic activity in vivo a. Prevention of formalin-induced carotid artery thrombosis: Topical application of formalin to a carotid artery of the guinea pig produces a local, occlusive, platelet-dependent thrombus within 5 hours (Beek, O. G. and Abrahams, S. L. Fed. Proc. 39, 423 (1980)). Twenty-five mg/kg p.o. of Compound II (adminis tered 1 hr. prior and again at 2 hr. post-formalin application) protected SoZ of the animals from thrombosis. The corresponding ED50's for aspirin and indomethacin were 2 x 35 mg/kg p.o. and 2 x 50 mg/kg p.o., respectively. b. Protection against stasis-induced jugular vein thrombosis: When a 1 cm length of guinea pig jugular vein is ligated in situ, a thrombus forms within 30 min. Six mg/kg p.o. of either Compound II or aspirin given 1 hour prior to ligation protected 50% of the animals from thrombosis. Example 9 Anti-Inflammatory Activity a. Carrageenin Pleurisy Assay (Acute): Following the procedure described by Vinegar et al. (Eur. J. Rheumatology and Inflammation, 1, 204 (1978)), Compound II is slightly less potent by the oral route than aspirin in the carrageenin pleurisy assay in the rat. In this assay, the 3 hr. ED50 is 37 mg/kg for Compound II vs. 28 mg/kg and 2 mg/kg, respectively, for aspirin and indomethacin against exudate fluid volume. b. Adjuvant Arthritis Assay (Chronic): When administered by gavage for 14 days, Compound II inhibits the development of adjuvant arthritis in the rat as determined by the method of Vinegar et al. (J. Immurophatmacology, 1, 497 (1979)). The ED50 was 294 mg/kg/day compared with 175 and 1 mg/kg/ day for aspirin and indomethacin, respectively. Example 10 Mild Analgesic Activity a. Acetic Acid Writhing Test Using the procedure described by Koster et al. (Fed. Proc., 18, 412 (1959)) and Vinegar et al. (Randbook of Experimental Pharmacology, 50-52, ch. 26, Anti Inflammatory Drugs, Ed. Vane, J. and Ferreria, S. (1978)) , the acetic acid writhing test was performed, using the rat, to demonstrate the mild analgesic activity of the compound of Formula (II). Compound II is approximately 2/3 and 1/10 as potent as aspirin and indomethacin, respectively, in the acetic acid writhing assay in the rat. b. Modified Trypsin Hyperalgesic Assay This assay quantitatively measures analgesia and is designed to be unaffected by compounds possessing anti-inflammatory activity alone. The procedure described by Vinegar et al. (Eur. J. Pharmacol., 37, 23 (1976)) was modified so that drug administration preceded subplantar injection of trypsin (0.10 my of a 0.10% solution of trypsin in pyrogen-free water) by 15 minutes. In the modified trypsin hyperalgesic assay, Compound II has an ED50 - 50 mg/kg p.c Aspirin and indomethacin are inactive in this assay. Example 11 Anti-Pyretic Activity The Yeast-Induced Hyperthermia Assay was used according to the procedure described by Khalili-Varasteh et al. (Arch. Int. Pharmacodyn, 219, 149 (1976)) to demonstrate antipyretic activity. Yeast-induced hyperthermia in the rat is completely reversed by 120 mg/kg p.o. of Compound II. Hypothermia was produced 3-4 hours after dosing. The ED50 for aspirin in this assay is 50 mg/kg p.o. Aspirin does not produce hypothermia. Example 12 Gastric Effects d. Rat: Compound II does not produce gastric damage in the rat after a single oral dose of 150 mg/kg (4x the acute anti-inflammatory 3 hr. ED50 and 15x the anti-platelet EDSd): or after 5 days of oral dosing at 75 mg/kg per day. A single oral dose of 30 mg/kg aspirin (anti-inflammatory 3 hr. ED50) produces ulcers and hemorrhages, while a single oral dose of 5 mg/kg indomethacin (2 1/2x the anti-inflammatory 3 hr. ED50) produces ulcers. b. Guinea pig: At 100 mg/kg/day p.o. for 3 days, Compound II produces very slight gastric erosion in the guinea pig. This is in contrast to the severe ulceration and hemorrhage produced by the same dose of aspirin. Example 13 Tablet Isethionate Salt of Compound II 600 mg Pregelatinized Corn Starch 70 mg Sodium Starch Glycolate 26 mg Magnesium Stearate 4 mg The Compound II Isethionate was finely ground and intimately mixed with the powdered excipients, pregelatinized corn starch and sodium starch glycolate. The powders were wetted with purified water to form granules. The granules were dried and mixed with the magnesium stearate. The formulation was then compressed into tablets weighting approximately 700 mg each. Example 14 Tablet Isethionate Salt of Compound II 300 mg Lactose 212 mg Corn Starch 60 mg Polyvinylpyrrolidone 12 mg Stearic Acid 12 mg Magnesium Stearate 4 mg The Compound II Isethionate was finely ground and intimately mixed with the powdered excipients, lactose and corn starch. The powders were wetted with a solution of polyvinylpyrrolidone dissolved in purified water and denatured alcohol to form granules. The granules were dried and mixed with the powdered stearic acid and magnesium stearate. The formulation was then compressed into tablets weighing approximately 600 mg each. Example 15 Capsule The Isethionate Salt of the Compound II 300 mg Lactose 173 mg Corn Starch 55 mg Stearic Acid 22 mg The finely ground Compound II Isethionate was mixed with the powdered excipients lactose, corn starch, and stearic acid and filled into hard-shell gelatin capsules. Example 16 Syrup Dihydrochloride of Compound II 250 mg Glycerin 500 mg Sucrose 3,500 mg Flavoring Agent q.s. Coloring Agent q.s. Preserving Agent q.s. Purified Water q.s. to 5 ml The Compound II dihydrochloride and sucrose were dissolved in the glycerin and a portion of the purified water. The preserving agent was dissolved in another portion of hot purified water and then the coloring agent was added and dissolved. The two solutions were mixed and cooled before the flavoring agent was added. Purified water was added to final volume. The resulting syrup was thoroughly mixed. Example 17 Injection Dihydrochloride Salt of Compound II 100 mg Sodium Chloride 8.5 mg Water for Injections q.s. to 1.0 ml The finely ground active compound and sodium chloride were dissolved in the Water for Injections. The solution was filtered, filled into ampules and sterilized by autoclaving. Example 18 Injection Dihydrochloride Salt of Compound II 100 mg Sodium Chloride 8.5 mg Preservative q.s. Water for Injection q.s. to 1.0 ml The finely ground active compound, sodium chloride, and preservative were dissolved in the water for injection. The solution was sterilized by membrane filtration, aseptically filled into sterile multi-dose vials and sealed with sterile rubber stoppers. Example 19 Tablet Monohydrochloride Salt of Compound II 550 mg Pregelatinized Corn Starch 70 mg Sodium Starch Glycolate 26 mg Magnesium Stearate 4 mg The Compound II monohydrochloride was finely ground and intimately mixed with the powdered excipients, pregelatinized corn starch and sodium starch glycolate. The powders were wetted with purified water to form granules. The granules were dried and mixed with the magnesium stearate. The formulation was then compressed into tablets weighing approximately 650 mg each. Example 20 Tablet Monohydrochloride Salt of Compound II 275 mg Lactose 237 mg Corn Starch 60 mg Polyvinylpyrrolidone 12 mg Stearic Acid 12 mg Magnesium Stearate 4 mg The Compound II monohydrochloride was finely ground and intimately mixed with the powdered excipients, lactose and corn starch. The powders were wetted with a solution of polyvinylpyrrolidone dissolved in purified water and denatured alcohol to form granules. The granules were dried and mixed with the powdered stearic acid and magnesium stearate. The formulation was then compressed into tablets weighing approximately 600 mg each. Example 21 Capsule Monohydrochloride Salt of Compound II 275 mg Lactose 68 mg Corn Starch 40 mg Sodium Lauryl Sulfate 2 mg Stearic Acid 15 mg The finely ground Compound II monohydrochloride was mixed with the powdered excipients lactose, corn starch, sodium lauryl sulfate, and stearic acid and filled into hard-shell gelatin capsules. Example 22 Tablet Compound II 500 mg Pregelatinized Corn Starch 70 mg Sodium Starch Glycolate 26 mg Magnesium Stearate 4 mg The Compound II was finely ground and intimately mixed with the powdered excipients, pregelatinized corn starch and sodium starch glycolate. The powders were wetted with purified water to form granules. The granules were dried and mixed with the magnesium stearate. The formulation was then compressed into tablets weighing approximately 600 mg each. Example 23 Tablet Compound II 250 mg Lactose 219 mg Corn Starch 55 mg Polyvinylpyrrolidone 11 mg Stearic Acid 11 mg Magnesium Stearate 4 mg The Compound II was finely ground and intimately mixed with the powdered excipients, lactose and corn starch. The powders were wetted with a solution of polyvinylpyrrolidone dissolved in purified water and denatured alcohol to form granules. The granules were dried and mixed with the powdered stearic acid and magnesium stearate. The formulation was then compressed into tablets weighing approximately 550 mg each. Example 24 Capsule Compound II 250 mg - Lactose 93 mg Corn Starch 40 mg Sodiu Lauryl Sulfate 2 mg Stearic acid 15 mg The finely ground Compound II was mixed with the powdered excipients lactose, corn starch, sodium lauryl sulfate, and stearic acid and filled into hard-shell gelatin capsules.

Claims: CLAIMS: 1) Compounds of the general formula EMI32.1 (in which R and R are identical or different and may be hydrogen; a lower alkyl having 1 to 4 carbons; phenyl; optionally substituted with one or more lower alkyl groups having from 1 to 4 carbons, Lower alkoxy groups having from 1 to 4 carbons or halogen atoms; phenyl-C1 4-alkyl optionally substituted on the phenyl ring with one or more lower alkyl groups having from 1 to 4 carbons, lower alkoxy groups having 1 to 4 carbons or halogen atoms; or R and R taken together with the adjacent nitrogen atom form a cyclic substituent of 5 or 6 members containing in addition to the said nitrogen atom an optional second heteroatom selected from the group consisting of oxygen, nitrogen and sulphur) and acid addition salts and solvates thereof. 2) Compounds as claimed in claim 1 wherein at least one of R and R represents an alkyl croup containing 1 or 2 carbon atoms. 3) Compounds as claimed in claim 1 or claim 2 wherein at least one of R and R represents a phenyl group optionally substituted by one or more radicals selected from methyl, ethyl, methoxy, ethoxy, bromo and chloro. 4) Compounds as claimed in any of claims 1 to 3 wherein at least one of R and R1 represents a phenyl-C1 4 alkyl group optionally substituted on the phenyl ring and/or the alkylene group by one or more radicals selected from methyl, ethyl, methoxy, ethoxy, bromo and chloro. 5) Compounds as claimed in any of claims 1 to 4 wherein at least one of R and R represents a benzyl or phenylethyl group optionally substituted on the phenyl ring by one or more radicals selected from methyl, ethyl, methoxy, ethoxy, bromo and chloro. 6) Compound as claimed in claim 1 wherein R and R' together with the adjacent nitrogen atom form a 5- or 6-membered ring optionally including a further heteroatom (in addition to the said nitrogen atom) selected from oxygen and nitrogen. 7) Compounds fo formula (I) as claimed in any of the preceding claims in the form of their hydrochloride, suLfate, hydrogen sulfate, isethionate, maleate, mesylate, phosphate or tart rat acid addition saLts. 8) 2-f2-E2-(Dimethylamino)ethoxyphenyL-4,5-diphenytimidazole and acid addition salts thereof. 9) 2-f2-±2-(DimethyLamino)ethoxy3phenyl-4,5-diphenylimidazole monohydrochloride. 10) 2-2-C2-(N-Methylbenzylamino)ethoxy3pheny Lj -4,5-di phenyl- imidazole and acid addition salts thereof. 11) A compound of formula (I) (as defined in claim 1) selected from 2-(2-(2-aminoethoxy)phenyl]-4,5-diphenylimidazole 2-{2-[2- (methylamino) et hoxy]phenyl# -4,5-diphenyl i mi dazo le 2-#2-[2-(diethylamino)ethoxyphenyl-4,5-diphenylimidazole 2-f2-C2-(4-methoxy-N-methylbenzylamino)ethoxyzphenyl)-4,5- diphenylimidazole 2-2-E2- (3,4-di met hoxy-N-met hy Lbenzy lami no) et hoxy3pheny 0 4,5-diphenylimidazole 2-#2-[2-(N,4-dimethylbenzylamino)ethoxy]phenyl#-4,5- diphenylimidazole 2-#2 E2- #4-ch lo ro-N-met hy lbenzy lami no) et hoxy3pheny -4,5- diphenylimidazole 4,5-diphenyl-2-f2-C2-(N-propylbenzylamino)ethoxy3phenrlf imidazole 2-t2-C2-dibenzylamino)ethoxy3pheny ,5-diphenylimidazole 2-{-(N-methylphenethylamino)ethoxy3phenyL3 -4,5diphenylimidazole 4,5-diphenyl-2-C2-(2-piperidinoethoxy)phenyl]imidazole 2-E2-(2-morpholinoethoxy)phenyL3-4,5-diphenylimidazoLe and 4,5-diphenyl-2-f2-±2-(1-pyrrolidinyl)ethoxy3phenyl3- imidazole, and physiologically acceptable acid addition salts and solvates thereof. 12) A process for the preparation of a compound of formula (I) (as defined in claim 1) or an acid addition salt thereof which comprises a) reacting an appropriÅate ,-diphenylethylene derivative with a 2-(2-aminoethoxy)phenyl compound to form a 2,4,5trisubstituted imidazole ring and consequent formation of a compound of formula (I); b) reacting a compound of formula EMI35.1 with a compound of formula EMI35.2 (wherein R and R' are as defined above and L is a leaving group); c) reacting an amine of formula HNRR' (wherein R and R' are as defined above) with a compound of formula EMI35.3 (wherein L is a leaving group) d) reacting a compound of. formula (I) (wherein at least one of R and R is hydrogen) with an appropriate alkylating, arylating or aralkylating agent to provide a corresponding compound of formula (I) wherein at least one of R and R is a lower alkyl, phenyl or phenyl-C1 4-alkyl group as defined above;or e) condensing an amine of formula HNRR1 (wherein R and R are as defined above) with a compound of formula EMI36.1 in the presence of a reducing agent; and optionally converting the resulting compound of formula (I) into an acid addition salt thereof. 13) Pharmaceutical formulations comprising, as active ingredient, at least one compound of formula EMI37.1 (in which R and R are identical or different and may be hydrogen; a lower alkyl having 1 to 4 carbons; phenyl optionally substituted with one or more lower alkyl groups having from 1 to 4 carbons, lower alkoxy groups having from 1 to 4 carbons or halogen atoms; phenyl-C1 4-alkyl optionally substituted on the phenyl ring with one or more lower alkyl groups having from 1 to 4 carbons, lower alkoxy groups having 1 to 4 carbons or halogen atoms: or R and R taken together with the adjacent nitrogen atom form a cyclic substituent of 5 or 6 members containing in addition to the said nitrogen atom an optional second heteroatom selected from the group consisting of oxygen, nitrogen and sulphur) or a physiologically acceptable acid addition salt or solvate thereof, together with at least one pharmaceutical carrier or excipient. 14) Pharmaceutical formulations as claimed in claim 13 in dosage unit form. 15) Pharmaceutical formulations as claimed in claim 13 or claim 14 adapted for oral, rectal or parenteral administration. 16) Pharmaceutical formulations as claimed in any of claims 13 to 15 wherein the active ingredient comprises 2-t2-C2- (dimethylamino)ethoxy3phenylj -4,5-diphenylimidazole or a physiologically acceptable acid addition salt or solvate thereof. 17) Pharmaceutical formulations as claimed in any of claims 13 to 15 wherein the active ingredient comprises 2-2-E2- (N-methylbenzylamino)ethoxy3phenylj-4,5-diphenylimidazole or a physiologically acceptable acid addition salt or solvate thereof. 18) Pharmaceutical formulations as claimed in any of claims 13 to 15 wherein the active ingredient comprises at least one compound as claimed in claim 11. 19) Compounds of formula (I) and their physiologically acceptable acid addition salts and solvates for use in a method of treatment of the human or animal body by therapy. 20) Compounds of formula CI) and their physiologically acceptable acid addition salts for use in the treatment or prophylaxis of thrombo-embolic conditions in a mammal. 21) 2- f2-E2-Cdimethylami no) ethoxyphenyl3-4,5-diphenyl imidazole or a physiologically acceptable acid addition salt or solvate thereof, for use in the treatment or prophylaxis of thromboembolic conditions in a mammal. 22) Compounds of formula (I) and their physiologicaLly acceptable acid addition salts for use in the treatment or prophylaxis of inflammatory conditions in a mammal 23) 212-CZ-(dimethytamino)ethoxy3pheny L3 -4,5-diphnylimidazole or a physiologically acceptable acid addition salt or solvate thereof for use in the treatment or prophylaxis of inflammatory conditions in a mammal. 24) Compounds of- formula (I) and their physiologically acceptable acid addition salts for use as an antipyretic. 25) 2-2-±2-(dimethylamino)ethoxy3phenyLJ -4,5-diphenylimidazole or a physiologically acceptable acid addition salt or solvate thereof for use as an antipyretic. 26) Compounds of formula (I) and their physiologically acceptable acid addition salts for use as an analgesic. 27) 2-f2-C2-(dimethylaminoZethoxy]phenyl3-4,5-diphenyl- imidazole or a physiologically acceptable acid addition salt or solvate thereof for use as.an analgesic.

Inventors: PHILLIPS, ARTHUR PAGE, ROSEN, SOLOMON, WHITE, HELEN LYNG
Applicants: THE WELLCOME FOUNDATION LIMITED
Application year: 1982
Main classification: C07D233
IPC codes: A61P7, C07D233, A61K31